AMED — Amedisys Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapSuper Stock

Annual income statement for Amedisys, fiscal year end - December 31st, USD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	10-K	10-K	10-K	10-K	10-K
Standards:	USG	USG	USG	USG	USG
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	2,072	2,214	2,223	2,236	2,348
Cost of Revenue
Gross Profit	886	1,015	972	991	1,018
Selling / General / Administrative Expenses
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	1,852	1,962	2,042	2,186	2,254
Operating Profit	219	252	181	50.4	94.5
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	211	280	160	39.6	86.2
Provision for Income Taxes
Net Income After Taxes	185	210	118	-10.9	38.2
Minority Interest
Net Income Before Extraordinary Items
Net Income	184	209	119	-9.75	43.2
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	184	209	119	-9.75	43.2
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	5.05	6.84	3.96	2.55	2.85